



Missouri Department of Health and Senior Services

P.O. Box 570, Jefferson City, MO 65102-0570 Phone: 573-751-6400 FAX: 573-751-6010
 RELAY MISSOURI for Hearing and Speech Impaired and Voice dial: 711



Robert Knodell
 Acting Director

Michael L. Parson
 Governor

April 20, 2021

Section 192.206. RSMo, authorizes the Director of the Department of Health and Senior Services to authorize a Missouri licensed physician to issue a statewide standing order for an opioid antagonist. Pursuant to said section, I hereby authorize Dr. George Turabelidze to issue such standing order.

This order and procedure shall remain in effect until rescinded.

Director Missouri Department of Health and Senior Services

April 20, 2021
 Date

This standing order authorizes any pharmacist practicing in the state of Missouri and licensed by the Missouri Board of Pharmacy to dispense the following naloxone products to persons as directed below.

Naloxone HCL Dispensing Protocol			
Eligible Candidates	<ul style="list-style-type: none"> ▪ Persons who voluntarily request naloxone and are at risk of experiencing an opiate-related overdose, including but not limited to: <ul style="list-style-type: none"> - Current illicit or non-medical opioid users or persons with a history of such use - Persons with a history of opioid intoxication or overdose and/or recipients of emergency medical care for acute opioid poisoning - Persons with a high dose opioid prescription (>50 morphine mg equivalents per day) - Persons with an opioid prescription and known or suspected concurrent alcohol use - Persons from opioid detoxification and mandatory abstinence programs - Persons entering methadone maintenance treatment programs (for addiction or pain) - Persons with opioid prescription and smoking/COPD or other respiratory illness or obstruction - Persons with an opioid prescription who also suffer from renal dysfunction, hepatic disease, cardiac disease, HIV/AIDS - Persons who may have difficulty accessing emergency medical services - Persons enrolled in prescription lock-in programs ▪ Persons who voluntarily request naloxone and are the family member or friend of a person at risk of experiencing an opiate-related overdose. ▪ Persons who voluntarily request naloxone and are in the position to assist a person at risk of experiencing an opiate-related overdose. 		
Route(s) of Administration	Intranasal (IN) <i>Preferred method</i>		Intramuscular (IM) Inject into shoulder or thigh
Medication and Required Device for Administration	Naloxone HCl 1mg/mL Inj. 2X2 mL as pre-filled Luer-Lock syringes <ul style="list-style-type: none"> ▪ Dispense 2 (two) doses 2 (two) X Intranasal Mucosal Atomizing Devices (MAD 300)	NARCAN® 4 mg/0.1 mL Nasal Spray <ul style="list-style-type: none"> ▪ Dispense 1 X two-pack 	<u>Naloxone HCl 0.4 mg/mL Inj.</u> <ul style="list-style-type: none"> ▪ 2 X 1mL single dose vials (SDV) ▪ 2 (two) 3 mL syringe ▪ 2 (two) 25 G, 1 inch needle Naloxone HCl 2 mg/2mL Inj. <ul style="list-style-type: none"> ▪ Dispense 2 (two) pre-filled syringes ▪ 2 (two) 25 G, 1 inch needle

www.health.mo.gov

Healthy Missourians for life.

The Missouri Department of Health and Senior Services will be the leader in promoting, protecting and partnering for health.

AN EQUAL OPPORTUNITY / AFFIRMATIVE ACTION EMPLOYER: Services provided on a nondiscriminatory basis.

Directions for Use	Call 911. Spray 1 mL in each nostril. Repeat every three minutes as needed if no or minimal response.	Call 911. Administer a single spray of NARCAN® in one nostril. Repeat every three minutes as needed if no or minimal response.	Call 911. Inject the entire solution of the vial or pre-filled syringe IM in shoulder or thigh. Repeat every three minutes as needed if no or minimal response.
Refills	PRN		
Contraindications	A history of hypersensitivity to naloxone or any of its components		
Patient Education	Every person dispensed naloxone under this standing order shall receive education regarding the risk factors of overdose, signs of an overdose, overdose response steps, and the use of naloxone.		



George Turabelidze, MD
 DEA # BT4964967

April 20, 2021
 This order is effective immediately upon signing.